TransMedics Beats Q3 by 75%, but Bears Hold 39% Float
TransMedics beat Q3 adjusted EPS estimates by 75% on record $203 million revenue, with service revenue growth accelerating to 60% year over year. Yet 39.3% of the float remains sold short, reflecting
TransMedics Beats Q3 Estimates; Bears Hold 39% Float
NEW YORK, November 8 —
TransMedics Group, Inc. (TMDX) beat Q3 2026 adjusted EPS estimates by 75% and posted record revenue of $203 million, the same scale of outperformance it delivered in Q4 2025, the quarter immediately before missing by 51% and then 8%. With 39.3% of the float sold short, the bears haven't moved, and they have a playbook to point to.
- Q3 revenue of $203 million rose 41% year over year; adjusted EPS of $0.51 beat the $0.29 consensus by 75%.
- Service revenue grew 60% year over year, outpacing 29% product growth; the stock surged 20.3% intraday to $83.
- Net debt stands at $380 million against trailing free cash flow of $22 million; short interest is 39.3% of float.
The Pattern That Built the Short
That short position is not a contrarian bet against a good business; it is a bet on a pattern. After Q4 2025, when the company beat estimates by 40%, TMDX then missed by 51% in Q1 2026 and by 8% in Q2. That sequence trained the market to treat big beats as mean-reversion setups rather than trend confirmations. The Q3 print, another outsized outperformance, lands in that exact context. Director David Weill bought 1,336 shares at $81.63 on September 11 before the report, an on-the-record vote of confidence below the post-earnings price. Whether that signal is prescient or noise depends on what Q4 delivers.
Services Rewired the Revenue Mix
TransMedics makes the Organ Care System, a portable perfusion platform that keeps donor lungs, hearts, and livers viable during transport, and beyond the hardware, operates a National OCS Program that handles aviation and ground logistics as a turnkey outsourced service. That services segment is now the company's growth engine: service revenue rose 60% year over year in Q3, ahead of the 29% product growth rate. Those gains came despite a 6% decline in overall U.S. deceased donor volume, which CEO Waleed Hassanein cited as a direct headwind alongside seasonal pressures. Liver and heart transplant volume gains absorbed that drag, pointing to market share expansion rather than pure volume riding.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| TMDX | $3.1B | 39.1x | -27.9% |
| OSCR | $9.5B | 13.8x | +109.8% |
| CELH | $8.1B | 19.2x | -27.8% |
| FOUR | $3.5B | 7.6x | -38.0% |
| DLO | $4.0B | 12.4x | -1.5% |
| CLPT | $276M | n/a | -48.0% |
What the Guidance Raise Doesn't Answer
Management raised full-year 2026 revenue guidance to $764, $774 million, implying 26%, 28% growth, and Canaccord Genuity raised its price target to $120, against a consensus of $102.55. At 39.1 times forward earnings, the market is pricing continued execution, and net debt of $380 million against trailing free cash flow of $22 million leaves little room for another stumble. The 2027 catalysts management named, ENHANCE Heart Part B and DENOVO Lung, are the levers that need to expand cash conversion alongside revenue. Run the TransMedics Group, Inc. deep-dive to track whether FCF begins closing that gap; the DCF calculator offers a check on the valuation multiple.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Did TransMedics beat Q3 earnings estimates?
TransMedics beat Q3 2026 adjusted EPS estimates by 75%, posting $0.51 against consensus of $0.29. The company also reported record revenue of $203 million, up 41% year over year.
Why do short sellers target TransMedics?
TransMedics has a pattern of mean reversion: after beating Q4 2025 estimates by 40%, it missed by 51% in Q1 2026 and 8% in Q2. That history has led 39.3% of the float to be sold short, betting another miss follows the Q3 beat.
What drove TransMedics service revenue growth?
Service revenue rose 60% year over year in Q3, outpacing 29% product growth, despite a 6% decline in overall U.S. deceased donor volume. Gains in liver and heart transplant volumes suggest market share expansion rather than pure volume riding.
What is TransMedics' debt position?
Net debt stands at $380 million against trailing free cash flow of $22 million, leaving limited room for execution missteps. Management raised 2026 revenue guidance to $764, $774 million, implying 26-28% growth.
Who is betting on TransMedics after Q3?
Director David Weill bought 1,336 shares at $81.63 on September 11 before the report, signaling an on-the-record vote of confidence ahead of the earnings release.
TransMedics Group posted record Q3 2026 revenue of $203 million, up 41% year over year, beat adjusted EPS estimates by 75%, and raised its full-year outlook — sending the stock surging more than 20% intraday. With 39.3% of the float still sold short, the market is now split on whether this quarter marks a genuine inflection or is a replay of Q4 2025, the last time TransMedics posted a big beat before missing in each of the two quarters that followed.